• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/16

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

16 Cards in this Set

  • Front
  • Back

What is the enzymatic activity for polymorphism CYP2C9*2?

60-70% of normal

What is the enzymatic activity for polymorphism CYP2C9*3?

5% or normal

What percentage of interindividual variability of warfarin dosing in caucasians can be explained by genetics?

30-40% can be explained by genetic polymorphisms.

Which genes contribute to variability in warfarin dosing?

CYP2C9 (5-15%)


VKORC1 (10-30%)


CYP4F2 (1-2%)

Which polymorphism of CYP2C9 is found in Asian populations?

*3 is found in 6-8% of Asian populations, whereas *2 is virtually nonexistant.

What are the 3 most common genotypes for VKORC1?

GG, AG, AA

What are the 2 common haplotypes of VKORC1?

A and B. Both are composed of 5 non-coding SNPs.

Define: haplotype


A combination of alleles that are commonly inherited together.

Which gene influences time to first therapeutic INR (efficacy)?

VKORC1 haplotypes.


CYP2C9 not associated.

Which gene influences time to get to INR>4 (toxicity)?

Both VKORC1 and CYP2C9

MOA of statins?

Statins inhibit HMG CoA reductase, which is used to convert acetyle CoA to mevalonate, a precursor to cholesterol.

What is a common side effect from statin use?

Myopathy (muscle pain or weakness with elevated creatinine kinase levels). Symptoms range from mild myalgia to rhabdomylosis. Can be up to 10% of clinical cases.

What are risk factors for myopathy?

1. High statin doses


2. Use of drugs that increase statin bioavailability


3. Genetics

What is the function of SLCO1B1 gene?

It codes for organic anion transporting polypeptide C (OAT 1B1).


This transports statins (except fluvastatin) to hepatocytes.

Effect of SLCO1B1*5 variant?

Amino acid change of 174Val/Ala, reducing OAT1B1 transport activity. This increases statin bioavailability, therefore is a risk factor of myopathy.

The genome wide association study for statins and cardiovascular events was useful.


T/F

True